Abstract
The recently licensed quadrivalent seasonal influenza vaccine (QIV) may provide better protection than the traditional trivalent influenza vaccine (TIV) as it includes one more influenza B strain. We developed a Monte Carlo simulation model to determine the economic value of a QIV compared to the TIV for 10 influenza seasons (1999-2009). The addition of the influenza B strain to convert the TIV into a QIV could result in substantial cost-savings to society (median of $3.1 billion) and third party payers (median of $292 million), even when the cost of QIV is significantly higher.
Original language | English (US) |
---|---|
Pages (from-to) | 7443-7446 |
Number of pages | 4 |
Journal | Vaccine |
Volume | 30 |
Issue number | 52 |
DOIs | |
State | Published - Dec 14 2012 |
Externally published | Yes |
Keywords
- Economics
- Influenza
- Quadrivalent vaccine
- Trivalent vaccine
ASJC Scopus subject areas
- Molecular Medicine
- General Immunology and Microbiology
- General Veterinary
- Public Health, Environmental and Occupational Health
- Infectious Diseases